The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

NCT ID: NCT02539017

Last Updated: 2016-08-10

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-11-30

Brief Summary

As a special type of breast cancer, the triple negative breast cancer has the characteristics of high recurrence rate (2 years after surgery), high distant metastasis rate, poor prognosis and short survival time. No matter at home or abroad, the clinical researches of the triple negative breast cancer are mainly focused on finding new drugs and new treatment strategies in order to reduce its recurrence and distant metastasis rate. The DC/CIK cell immunotherapy combined with chemotherapy in the clinical study of metastatic triple negative breast cancer has already confirmed benefit. This study is based on the theory that the optimal timing of cellular immunity is while the host tumor load is under the smallest state. Put forward the hypothesis that the DC/CIK cell immunotherapy combined with chemotherapy may improve the disease-free survival and overall surviva after the triple negative breast cancer operation. The investigators intends to use the RCT, observing the clinical significance of cellular immune adjuvant therapy of triple negative breast cancer in 340 patients with TNBC. Do the safety evaluation of cellular immunity in the adjuvant treatment of breast cancer treatment, explore the clinical strategies for breast cancer immunotherapy.

Conditions

Triple Negative Breast Neoplasms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Combined

Combined Chemo Therapy and immunotherapy with double dendritic cell (DC) and cytokine-induced killer (CIK) cell

Group Type: EXPERIMENTAL

Chemo

Intervention Type: DRUG

Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles

Immunotherapy

Intervention Type: BIOLOGICAL

Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell

Chemo

Control group: Chemo Therapy group

Group Type: ACTIVE_COMPARATOR

Chemo

Intervention Type: DRUG

Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles

Interventions

Chemo

Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles

Intervention Type: DRUG

Immunotherapy

Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Age: ≥18 years old
• ECOG score: ≤1
• the Primary invasive ductal carcinoma which are during the Ib period to IIIc and should be surgical resection while no distant metastasis (except for the tumor of N3 in the internal mammary region, the above clavicle LN), and the diagnosis of the tumor was confirmed by pathological diagnosis;
• There must be no residual in the surgical margin(except lobular carcinoma in situ), and the remove number of axillary lymph nodes in the same side must be above 10 (except for the negative sentinel lymph nodes).
• Have the results of the immunohistochemical detection of ER, PR and HER2, the one whose HER2+ and HER2++ should be confirmed by FISH.
• The chemotherapy regimens recommended by the guide and radiation therapy (qualified).
• Have normal tissue and organ function:

Bone marrow function: ANC must be≥1.5×109/L, the platelet count must be≥100×109/L , hemoglobin must be ≥10g/dL.

Renal function: serum creatinine must be≤1.5ULN Liver function: total bilirubin ≤1.5ULN，AST≤1.5ULN，ALT≤1.5ULN

• The results of imaging examination of the contralateral breast molybdenum, chest CT, abdominal B ultrasound and whole body bone scan should be required before the random.
• Sign the informed consent form.
• Have a good compliance, and can be follow-up for at least 5 years.

Exclusion Criteria

• have the past history of breast cancer with the same or opposite side, a history of immune system diseases.
• T1aN0M0, inflammatory breast cancer and bilateral breast cancer; patients with T cell lymphoma.
• Have the history of other malignant tumors before (except for the cervical carcinoma in situ, squamous cell carcinoma of the skin, skin basal cell carcinoma).
• Have the important organ dysfunction of heart, lung, liver, kidney and others.
• People who are pregnant or unwilling to use contraception during treatment.
• Patients who have received organ transplantation or long-term use of immunosuppressive agents.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

First Affiliated Hospital Xi'an Jiaotong University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yu Ren, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

First Affiliated Hospital Xi'an Jiaotong University

Locations

the First Affiliated Hospital of Xi 'an Jiaotong University

Xi'an, Shaanxi, China

Countries

China

Other Identifiers

Renyu-012

Identifier Type: -

Identifier Source: org_study_id